[ Inside the business ]

RVTY stock analysis

RVTY · Revvity, Inc.

Laboratory analytical instruments. Growing 4%. Keeps 13¢ of every dollar.

Nothing unusual in its latest filings.

The future, in 7 questions

Priced in: 2.2× sales in 5 yrs. Evidence: sales +4% · 13¢ profit/$1.

01 What's priced in?2.2× sales in 5 yrs
Sales now$2.9B
Needed in 5 yrs$6.5B
02 Is the wave rising?No Radar technology matched

Not among the companies mentioning Radar's technologies most.

03 Will customers keep buying?Sales +4%, steady
No customer over 10%
Prepaid $236MSales +4%, steady
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Keeps 13¢ per $1
'22'23'23'24'2513¢
Before running costs: 48% → 60%
06 Can it fund itself?Pays its own way
05 yrsself-funded
Shares −3.3%/yrDebt $2.6B
07 What could break it?1 to watch
  • Moves strongly with the S&P 500

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth speeding up.

Sales growth +7%, +1%, then +4% vs. a year ago.

What could go wrong

Few warning signs.

It has moved 1.1× the market. In the 2008 crisis it fell 52% while the market fell 51%. Debt is heavy.

Speculative check

Self-funding.

Passes every condition: profitable, cash-generating and financially sound.

What they sell

83% Product.

Product 83% · Service 17%

Where each dollar goes

13¢ profit.

49¢ to make what it sells, 43¢ on research and overhead, 13¢ left over. Revenue $2.9B in the last 12 months.

Its market

0.6× the economy.

The government expects its industry, navigational, measuring, electromedical, and control instruments manufacturing, to grow 1.1% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Maturity.

It earns cash, still invests, and pays back more than it borrows.

Earnings quality

Can't score.

Not available: some of the eight inputs aren't in the company's structured filings (common for banks, insurers and companies without a cost of goods line).

Competitive advantage

1 of 10 years.

Returns beat its 8.7% cost of capital in 1 of the last 10 years. Gross margin went from 48% to 60%.

Future bets

7% on research.

$213M a year on R&D. $65M on equipment and buildings.

All figures from Revvity, Inc.'s SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.